In this study we found that serum inhibitory activity against Blastomyces dermatitidis was principally mediated by albumin. This was confirmed in experiments using albumin from several mammalian species. Analbuminemic rat serum did not inhibit B. dermatitidis growth in vivo; however, the addition of albumin restored inhibitory activity. Inhibitory activity does not require albumin domain III and appears to involve binding of a low-molecular-weight yeast-derived growth factor.Blastomyces dermatitidis is a thermally dimorphic fungal pathogen that infects humans, dogs, and other mammals (2,4,11,26,27). Blastomycosis occurs following inhalation of B. dermatitidis conidia, which change into a pathogenic yeast form in the lungs. The resulting pulmonary infection can range in severity from mild to acute and can lead to disseminated disease (3,4,11,25). Relatively little is known about components of the innate immune system that limit the multiplication of the yeast form of B. dermatitidis during the early stages of infection.Innate immunity is mediated by several mechanisms that serve as important first lines of host defense against microbial pathogens. Human serum contains several factors (i.e., transferrin, lactoferrin, lysozyme, and complement) that can inhibit or kill pathogenic microorganisms. The inhibitory effect of serum on most pathogenic fungi is dependent on the ironbinding activity of transferrin, which is reported to inhibit the growth of Candida albicans, Histoplasma capsulatum, Cryptococcus neoformans, and Penicillium marneffei in vitro (1,19,20,27,(31)(32)(33)35). In a previous study, we demonstrated that serum inhibits B. dermatitidis yeast form growth in vitro via a mechanism that is independent of transferrin (12). Other prominent serum factors, such as complement components and natural antibodies, do not inhibit B. dermatitidis yeast form growth in vitro (13). In the present study, we sought to elucidate the identity of the serum factor that mediates inhibitory activity against B. dermatitidis.Preliminary experiments indicated that protein fractions smaller than 100 kDa possessed inhibitory activity against B. dermatitidis (data not shown). The most abundant protein present in these fractions was albumin. Although it seemed unlikely, we assessed whether albumin could exert inhibitory activity against B. dermatitidis. To do so, B. dermatitidis yeast cells were suspended in RPMI 1640 medium supplemented with fraction V bovine serum albumin (BSA; at 1 mg/ml, which is equivalent to the albumin concentration of 5% fetal bovine serum [FBS]), and viable yeast cells were quantified as described previously (12). To our surprise, we found that BSA inhibited the growth of B. dermatitidis yeast cells to an extent similar to that of 5% FBS (Fig. 1A). This activity was not restricted to BSA since human (Fig. 1B), mouse (Fig. 1C), and canine ( Fig. 1D) fraction V serum albumin proteins also significantly (P Ͻ 0.01) inhibited B. dermatitidis growth.These unexpected results prompted us to explore the novel possibili...